Tamoxifen and Angiogenesis in the Endometrium
Author Information
Author(s): S Hague, S Manek, M K Oehler, I Z MacKenzie, R Bicknell, M C P Rees
Primary Institution: Nuffield Department of Obstetrics and Gynaecology, Women's Centre, John Radcliffe Hospital, Oxford, UK
Hypothesis
Does tamoxifen therapy change the expression of angiogenic factors in the endometrium?
Conclusion
Tamoxifen exposure increases the expression of several angiogenic factors and vascular density in the endometrium, particularly in premenopausal women.
Supporting Evidence
- Tamoxifen increased the expression of acidic and basic fibroblast growth factor and adrenomedullin in premenopausal endometrium.
- Vascular density was significantly higher in premenopausal endometrium after tamoxifen treatment.
- Endothelial proliferation index did not significantly change across the menstrual cycle.
Takeaway
Tamoxifen, a breast cancer treatment, can make the lining of the uterus grow more blood vessels, which might be a problem for some women.
Methodology
The study involved immunohistochemical analysis of endometrial samples from premenopausal and postmenopausal women treated with tamoxifen, assessing the expression of various angiogenic factors and vascular density.
Potential Biases
Potential bias in sample selection and the retrospective nature of the study.
Limitations
The study was limited to a specific population and may not generalize to all women using tamoxifen.
Participant Demographics
30 normal premenopausal women (aged 30–45) and 10 postmenopausal women (aged 59–84) were included.
Statistical Information
P-Value
0.0018
Statistical Significance
p=0.0018
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website